Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Secondary hyperparathyroidism is a common complication of patients with chronic kidney disease. Treatment with calcitriol, the active form of vitamin D, reduces parathyroid hormone levels, but may result in elevations in serum calcium and phosphorus. New vitamin D analogues have been developed to reduce parathyroid hormone secretion without concomitant hypercalcaemia and hyperphosphataemia. Recent data from studies with paricalcitol capsules, the oral formulation of 19-nor-1,25(OH)2D2, show a significant reduction in parathyroid hormone levels with no change in calcium and phosphorus levels when compared with placebo. Paricalcitol also compares favourably to other oral vitamin D analogues, effectively decreasing parathyroid secretion with less hypercalcaemia and hypercalciuria than other agents.

Original languageEnglish
Pages (from-to)617-621
Number of pages5
JournalExpert Opinion on Pharmacotherapy
Volume7
Issue number5
DOIs
StatePublished - Apr 1 2006

Keywords

  • Active vitamin D
  • Hypercalcaemia
  • Hyperphosphataemia
  • Paricalcitol

Fingerprint Dive into the research topics of 'Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease'. Together they form a unique fingerprint.

Cite this